Millennium Management
CRNX

Millennium Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

Millennium Management’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-62,368
Closed -$2.27M – 5939
2026
Q1 		$2.27M Sell
62,368
-237,967
-79% -$10.6M ﹤0.01% 3755
2025
Q4 		$14M Buy
300,335
+84,091
+39% +$3.74M 0.01% 1915
2025
Q3 		$9.01M Sell
216,244
-141,433
-40% -$4.52M ﹤0.01% 2492
2025
Q2 		$10.3M Buy
357,677
+350,989
+5,248% +$10.8M 0.01% 2226
2025
Q1 		$224K Buy
+6,688
New +$250K ﹤0.01% 5252
2024
Q3 		– Sell
-43,184
Closed -$1.93M – 6151
2024
Q2 		$1.93M Sell
43,184
-221,827
-84% -$10.2M ﹤0.01% 3565
2024
Q1 		$12.4M Sell
265,011
-108,618
-29% -$4.25M 0.01% 1990
2023
Q4 		$13.3M Buy
373,629
+91,030
+32% +$2.79M 0.01% 1925
2023
Q3 		$8.4M Buy
282,599
+240,071
+565% +$4.95M ﹤0.01% 2208
2023
Q2 		$766K Sell
42,528
-52,279
-55% -$1.04M ﹤0.01% 4235
2023
Q1 		$1.52M Sell
94,807
-480,681
-84% -$8.9M ﹤0.01% 3696
2022
Q4 		$10.5M Buy
575,488
+253,736
+79% +$4.47M 0.01% 2072
2022
Q3 		$6.32M Sell
321,752
-187,578
-37% -$3.83M ﹤0.01% 2663
2022
Q2 		$9.5M Buy
509,330
+273,170
+116% +$5.45M 0.01% 2098
2022
Q1 		$5.18M Buy
236,160
+203,201
+617% +$4.11M ﹤0.01% 2892
2021
Q4 		$936K Buy
32,959
+20,847
+172% +$514K ﹤0.01% 4465
2021
Q3 		$255K Buy
+12,112
New +$253K ﹤0.01% 5931
2021
Q1 		– Sell
-14,538
Closed -$205K – 6003
2020
Q4 		$205K Buy
+14,538
New +$202K ﹤0.01% 4794
2020
Q3 		– Sell
-113,034
Closed -$1.98M – 4501
2020
Q2 		$1.98M Buy
+113,034
New +$1.93M ﹤0.01% 2543
2020
Q1 		– Sell
-18,041
Closed -$453K – 3942
2019
Q4 		$453K Sell
18,041
-37,108
-67% -$706K ﹤0.01% 3447
2019
Q3 		$829K Buy
+55,149
New +$1.07M ﹤0.01% 2960
2019
Q2 		– Sell
-8,888
Closed -$202K – 4099
2019
Q1 		$202K Buy
+8,888
New +$218K ﹤0.01% 3731

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management's CRNX Position: Q2 2026 in Review

Millennium Management sold out of Crinetics Pharmaceuticals (CRNX) in Q2 2026, closing a stake of 62,368 shares — an estimated $2.27M sold.

Millennium Management first reported a position in CRNX in Q1 2019 and held it in 22 quarters. The position peaked at $14M in Q4 2025. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • Millennium Management reported no remaining Crinetics Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Millennium Management sold 62,368 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $2.27M.
  • Millennium Management first reported a position in Crinetics Pharmaceuticals in Q1 2019 and held it in 22 quarters.
  • Millennium Management's Crinetics Pharmaceuticals position peaked at $14M in Q4 2025.
  • 267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.